Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany.
BMC Cancer. 2012 Jul 28;12:317. doi: 10.1186/1471-2407-12-317.
Studies have revealed both higher cancer survival in the US than in Germany and substantial improvement of cancer survival in the past in these countries. This population-based study aims at comparing most recent 5-year relative survival of breast cancer patients and preceding trends in both countries.
Women with a first invasive breast cancer diagnosed and followed up between 1988 and 2008 from Germany and the US (utilizing data from the Saarland Cancer Registry and the Surveillance, Epidemiology, and End Results Program, respectively) were included. Period analysis was used to derive most up-to-date 5-year relative survival and preceding survival trends according to age and stage.
Since 1993, age standardized relative survival has steadily improved in Germany and the US to 83% and 88%, respectively. In the period 2005-08, relative survival of localized cancer was above 97% in both countries, and 79% and 83% for locally/regionally spread breast cancer, respectively. Prognosis of metastasized disease has remained very poor overall, with improvement essentially being restricted to younger patients. The proportion of patients diagnosed with localized breast cancer was consistently higher in the US. If adjusted for stage, the differences in relative survival between both countries diminished over time and eventually disappeared.
Similar survival is now observed in both countries for patients below the age of 70 years, but in Germany survival is still much lower for elderly patients. The observed trends point to treatment advances as a major cause for improved survival. However, substantial differences in mammography usage existed between both countries and might probably also account for the observed differences (to a lesser extent, also differences in health care systems, and delivery of cancer care). Encouraging, survival of breast cancer patients has improved in Germany to a much greater extent than in the US, albeit the persisting survival gap for elderly patients in Germany requires particular attention by researchers, public health authorities, and clinicians.
研究表明,美国的癌症生存率高于德国,且两国在过去都取得了显著的癌症生存率提高。本项基于人群的研究旨在比较两国最近的乳腺癌患者 5 年相对生存率以及既往的变化趋势。
纳入了分别在德国和美国(利用来自萨尔兰癌症登记处和监测、流行病学和最终结果计划的数据)于 1988 年至 2008 年间诊断和随访的首位浸润性乳腺癌女性患者。采用时期分析来根据年龄和分期推导最新的 5 年相对生存率以及既往的生存趋势。
自 1993 年以来,德国和美国的年龄标准化相对生存率分别稳定提高到 83%和 88%。在 2005-08 年间,两国局限性癌症的相对生存率均超过 97%,局部/区域性播散性乳腺癌的生存率分别为 79%和 83%。转移性疾病的总体预后仍然非常差,仅年轻患者的生存率有所提高。美国局部乳腺癌患者的比例一直较高。如果按分期调整,两国之间的相对生存率差异随时间推移逐渐缩小,最终消失。
目前两国 70 岁以下患者的生存率相似,但德国老年患者的生存率仍然较低。观察到的趋势表明,治疗进展是生存率提高的主要原因。然而,两国之间在乳房 X 线摄影的使用方面存在很大差异,这可能也是导致生存率差异的原因(在较小程度上,还存在医疗保健系统和癌症护理的提供方面的差异)。令人鼓舞的是,德国的乳腺癌患者生存率提高的幅度远大于美国,尽管德国老年患者的生存率仍存在差距,这需要研究人员、公共卫生当局和临床医生特别关注。